Australian medicinal cannabis firm Cann has moved quickly to maximise the benefits of its CBD Gelpell capsule technology by entering into a collaboration deal with healthcare technology firm Emyria ...
Restricted content. Do you want to read more?
Sign up NOW for 7 days FREE TRIAL and access our briefings section
CBD-Intel provides impartial, independent and premium market and regulatory analysis, legal tracking, and quantitative data for the cannabidiol (CBD) sector worldwide. Most content is available to subscribers only.